STOCKHOLM, Sweden--(BUSINESS WIRE)--Nanologica enters into a License and Collaboration Agreement with Alcyone Lifesciences to develop Abela – a treatment for motor neuron disorders including ALS. Nanologica today announced that it has entered into a License and Collaboration Agreement with Alcyone Lifesciences to develop a novel therapeutic platform named Abela; ‘to breathe’ in Hebrew. The partners want to combine Nanologica’s NLAB SilicaTM with Alcyone’s proprietary drug delivery platform tech
![]()
↧